Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

648
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
648
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

123
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perceptions of secure text messaging systems: a cross-sectional survey of hospitalist physicians and advanced practice providers.

Postgraduate medicine·2026
Same author

Right Atrial Vegetation on a Chiari Network Presenting With Multifocal Pulmonary Lesions.

Cureus·2026
Same author

Heat Stress and Non-Traditional Chronic Kidney Disease (CKDnt) Among Nepali Migrant Workers: A Climate-Sensitive Global Health Perspective.

Cureus·2026
Same author

Sponsorship: A Vital Leadership Strategy for Career Advancement in Academic Medicine.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

A Case of Autoimmune Thyroiditis Presenting as Apraxia.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

A Challenging Case of Creutzfeldt-Jakob Disease Presenting as Stroke.

WMJ : official publication of the State Medical Society of Wisconsin·2026

Related Experiment Video

Updated: Jul 23, 2025

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

4.4K

Olmesartan-Induced Enteropathy: A Case Report.

Dharmikkumar Jadvani1, Pinky Jha2, Meenu Singh3

  • 1Internal Medicine, Byramjee Jeejeebhoy (BJ) Medical College, Ahmedabad, IND.

Cureus
|July 17, 2023
PubMed
Summary

Olmesartan-induced enteropathy causes unexplained diarrhea and weight loss. Discontinuing olmesartan medication rapidly resolved symptoms in a patient, highlighting its importance in diagnosis.

Keywords:
adverse drug effectceliac spruediarrhea and abdominal painolmesartan-induced enteropathyvillous atrophy

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

651

Related Experiment Videos

Last Updated: Jul 23, 2025

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

4.4K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

651

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pharmacology

Background:

  • Olmesartan-induced enteropathy is a rare adverse drug reaction.
  • It presents with chronic diarrhea and weight loss, mimicking other small intestine diseases.
  • Timely diagnosis is often challenging due to overlapping clinical and histological features.

Observation:

  • A 58-year-old male on long-term olmesartan developed severe diarrhea, weight loss (35 lbs), acute kidney injury, and hypokalemia.
  • Extensive investigations including upper and lower endoscopy with biopsies, autoimmune markers, and infectious disease workup were negative.
  • Symptoms emerged during travel, suggesting a potential environmental or drug-related trigger.

Findings:

  • Olmesartan-induced enteropathy was diagnosed as a diagnosis of exclusion.
  • Discontinuation of olmesartan led to rapid improvement and resolution of diarrhea within days.
  • This case underscores the gastrointestinal side effects of olmesartan.

Implications:

  • Early recognition and drug withdrawal are crucial for managing olmesartan-induced enteropathy.
  • Physicians should consider this diagnosis in patients with unexplained chronic diarrhea on olmesartan.
  • Further research into the pathogenesis and diagnostic markers is warranted.